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Background: Previously, we have shown that microencapsulated allogeneic mesenchymal stem cells (MSCs) improve angiogenesis and 
arteriogenesis compared to non-encapsulated MSCs in a rabbit model of peripheral arterial disease1. Whether this improvement is related to 
enhanced cell survival due to immunoprotection or enhanced ability of the MSCs to release pro-angiogenic cytokines in response to hypoxia is not 
clear. The objective of the in vitro current study was to evaluate the response to hypoxia of microencapsulated and non-encapsulated human MSCs 
(hMSCs).
methods: Early passage hMSCs were microencapsulated in a 2% alginate solution or perfluorocarbon-modified alginate (PFOB) containing 106 
hMSCs /ml alginate. Encapsulated and non-encapsulated MSCs were subjected to 1% oxygen conditions for 4 hours and compared to controls in 
normoxic conditions (5% CO2). Alginate and PFOB capsules were lysed with citric acid and Versene and proteins were isolated. Western immunoblots 
were probed with anti-human hypoxia inducible factor-1α (HIF-1α) monoclonal antibody.
results: Immunoblot analysis of cell lysates revealed increased level of HIF-1α expression in all experimental arms cultured in hypoxia as 
compared to control, with a trend towards less HIF-1α in encapsulated cells relative to cancer or naked cells (P<0.07). PFOB encapsulated hMSCs 
demonstrated production of a small amount of HIF-1α when cultured in normoxia (0.09±0.06) and hypoxia (0.02±0.01).
discussion:  MSCs showed evidence of less hypoxic protein upregulation when they are encapsulated, suggesting that encapsulation may be the 
most beneficial for angiogenic recruitment in PAD therapy.
references: (1) Kedziorek et al. Stem Cells, 2012.
